Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread

Given the unclear preference criteria for regorafenib in treating refractory metastatic colorectal cancer (mCRC), this study aimed to construct an algorithm in selecting right patients for regorafenib. This was a multicenter retrospective cohort study. Patients with pathology confirmed mCRC and admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hung-Chih, Huang, Kuo-Cheng, Chen, Wei-Shone, Jiang, Jeng-Kai, Yang, Shung-Haur, Wang, Huann-Sheng, Chang, Shih-Ching, Lan, Yuan-Tzu, Lin, Chun-Chi, Lin, Hung-Hsin, Huang, Sheng-Chieh, Cheng, Hou-Hsuan, Yang, Tsai-Sheng, Chen, Chien-Chih, Chao, Yee, Teng, Hao-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319410/
https://www.ncbi.nlm.nih.gov/pubmed/34321583
http://dx.doi.org/10.1038/s41598-021-94968-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319410/
https://www.ncbi.nlm.nih.gov/pubmed/34321583
http://dx.doi.org/10.1038/s41598-021-94968-x

Ejemplares similares